ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

SKP alleviates the ferroptosis in diabetic kidney disease through suppression of HIF-1α/HO-1 pathway based on network pharmacology analysis and experimental validation

Yan, Yangtian; Yuan, Ningning; Chen, Yuchi; Ma, Yun; Chen, Ali; Wang, Fujing; Yan, Shihua; He, Zhuo'en; He, Jinyue; Zhang, Chi; Wang, Hao; Wang, Mingqing*; Diao, Jianxin*; Xiao, Wei*广东药学院; 南方医科大学
Chinese Medicine2024-2-25DOI: 10.1186/s13020-024-00901-5
25阅读
引用收藏
分享

摘要

Background Diabetic kidney disease (DKD) represents a microvascular complication of diabetes mellitus. Shenkang Pills (SKP), a traditional Chinese medicine formula, has been widely used in the treatment of DKD and has obvious antioxidant effect. Ferroptosis, a novel mode of cell death due to iron overload, has been shown to be associated with DKD. Nevertheless, the precise effects and underlying mechanisms of SKP on ferroptosis in diabetic kidney disease remain unclear. Methods The active components of SKP were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. Protein-protein interaction (PPI) network and Herb-ingredient-targets gene network were constructed using Cytoscape. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were conducted utilizing the Metascape system database. Additionally, an in vivo model of DKD induced by Streptozotocin (STZ) was established to further investigate and validate the possible mechanisms underlying the effectiveness of SKP. Results We retrieved 56 compounds and identified 223 targets of SKP through the TCMSP database. Key targets were ascertained using PPI network analysis. By constructing a Herb-Ingredient-Targets gene network, we isolated the primary active components in SKP that potentially counteract ferroptosis in diabetic kidney disease. KEGG pathway enrichment analysis suggested that SKP has the potential to alleviate ferroptosis through HIF signaling pathway, thereby mitigating renal injury in DKD. In animal experiments, fasting blood glucose, 24 h urine protein, urea nitrogen and serum creatine were measured. The results showed that SKP could improve DKD. Results from animal experiments were also confirmed the efficacy of SKP in alleviating renal fibrosis, oxidative stress and ferroptosis in DKD mice. These effects were accompanied by the significant reductions in renal tissue expression of HIF-1 alpha and HO-1 proteins. The mRNA and immunohistochemistry results were the same as above. Conclusions SKP potentially mitigating renal injury in DKD by subduing ferroptosis through the intricacies of the HIF-1 alpha/HO-1 signaling pathway.

学科与关键词

关键词
Diabetic kidney disease (DKD)Shenkang pills (SKP)FerroptosisNetwork pharmacologyHIF-1 alpha/HO-1 signaling pathway
相关
加载中…
  • Effects of Shenkang Pills on Early-Stage Diabetic Nephropathy in db/db Mice via Inhibiting AURKB/RacGAP1/RhoA Signaling Pathway
    Wang, Fujing; Fan, Jia'er; Pei, Tingting; He, Zhuo'en; Zhang, Jiaxing; Ju, Liliang; Han, Zhongxiao; Wang, Mingqing*; Xiao, Wei*Frontiers in Pharmacology, 2022, 13: 781806.被引 5
  • San-Huang-Yi-Shen capsule ameliorates diabetic nephropathy in mice through inhibiting ferroptosis
    Lv, Shuquan; Li, Huajun; Zhang, Tianyu; Su, Xiuhai; Sun, Wenjuan; Wang, Qinghai; Wang, Lixin; Feng, Nana; Zhang, Shufang*; Wang, Yuansong*; Cui, Huantian*Biomedicine and Pharmacotherapy, 2023, 165: 115086.被引 2
  • Network Pharmacology Approach to Investigate the Mechanism of Danggui-Shaoyao-San against Diabetic Kidney Disease
    Chen, Yulian; Song, Xiaodan; Luo, Yunxia; Li, Guandong; Luo, Yueming; Wang, Ziyan; He, Riming; Lu, Jiandong; Xiong, Guoliang; Cheng, Hong*; Li, Huilin*; Yang, Shudong*Evidence-based Complementary and Alternative Medicine, 2023, 2023: 9208017.
查看全部 →

发表信息

论文状态
公开发表
期刊
Chinese Medicine
发表日期
2024-02-25
卷期
第 19 卷, 第 1 期
页码
31
DOI
10.1186/s13020-024-00901-5
语言
ENGLISH
成果收录
SCIE
资助标注
National Foundation for Natural Scientific Research of China [82174322, 82004336, 82074257]; Natural Science Foundation of Guangdong Province, China [2023A1515011200]; Science and Technology Program of Guangzhou [SL2022A04J01029]; Innovation Team Project of Guangdong Province [2023KCXTD019]

作者

  • Y

    Yan, Yangtian (第一作者)

    southern med univ

  • Y

    Yuan, Ningning

    southern med univ

查看全部 14 位作者收起作者
  • C

    Chen, Yuchi

    southern med univ

  • M

    Ma, Yun

    southern med univ

  • C

    Chen, Ali

    guangdong pharmaceut univ

  • W

    Wang, Fujing

    southern med univ

  • Y

    Yan, Shihua

    southern med univ

  • H

    He, Zhuo'en

    southern med univ

  • H

    He, Jinyue

    southern med univ

  • Z

    Zhang, Chi

    southern med univ

  • W

    Wang, Hao

    southern med univ

  • W

    Wang, Mingqing (通讯)

    southern med univ

  • D

    Diao, Jianxin (通讯)

    southern med univ

  • X

    Xiao, Wei (通讯)

    southern med univ · guangdong pharmaceut univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417